Senti Biosciences, Inc.

Senti Biosciences, Inc. entered the public markets through a business combination with Dynamics Special Purpose Corp (Nasdaq: DYNS), a life sciences-focused blank-check company that completed its IPO in 2021 and was co-sponsored by Casdin Capital and Viking Global Investors. The company filed an S-1 registration statement on June 28, 2022, under accession number 0001193125-22-183907, reflecting its status as a newly listed public entity following the de-SPAC transaction. Senti Biosciences operates in the synthetic biology sector, developing programmable gene circuit-based cell and gene therapies. Investors seeking detailed filing history, sponsor profiles, and deal analytics for DYNS and comparable transactions can sign up for full data access at SpacDesk.